Arthritis, Joint Pain
Osteoarthritis pain reduced by 50% with new treatment12 Mar 2018
Pharmaceutical company Paradigm has reported a 50% reduction in pain with a new treatment for osteoarthritis.
This follows a recent trial with 45 patients with osteoarthritis (OA) after treatment with the injectable Pentosan Polysulfate Sodium (PPS).
In the 45 patients treated, 84.4% responded with both a reduction in joint pain and an improvement in knee function.
The 50% reduction in pain scores observed with PPS is considered superior than the typical 15% pain reduction scores reported for opioid treatments for chronic pain in OA of the knee and hip, says Paradigm.
All patients were symptomatic with OA pain for at least six months and had failed current standard of care which involved treatment with analgesics, NSAIDs (non-steroidal anti- inflammatory drugs) or corticosteroids.
Patients were administered with two injections of PPS per week for three to six weeks depending on the severity of their condition.
No NSAIDs or corticosteroid treatment
Patients were followed up at four weeks following the last treatment.
During the course of PPS treatment, patients did not receive NSAIDs or corticosteroid treatment.
Clinical knee pain outcome measures after the initiation of PPS treatment were:
• 18 out of 21 - (85.7%) patients showed a reduction in pain?
Clinical knee function outcome measures after the initiation of PPS treatment:
• 19 out of 21 - (90.4%) patients showed improvement in knee function
Paul Rennie, Paradigm’s Chief Executive Officer said: “It is a significant positive outcome that all these patients have on average, a clinically meaningful reduction in pain of 50%.
“Given these patients have a very similar treatment regimen to subjects being treated under the current Phase 2b Osteoarthritis randomised, double-blind, placebo-controlled, clinical trial and these patients have failed current therapies to treat OA, we remain confident of a positive clinical trial outcome, with the expected release of top line results for that trial due in Q4 CY 2018.”
In Australia, injectable PPS for human use is not currently available for sale.
Injectable PPS for human use is only available by inclusion into a Paradigm Sponsored clinical trial or via a treating physician applying for its use in patients via the TGA’s SAS - Category B.